FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000853219> ?p ?o ?g. }

• W2000853219 endingPage "270" @default.
• W2000853219 startingPage "264" @default.
• W2000853219 abstract "Objective. Glutamatergic dysregulation is implicated in the pathophysiology of fragile X syndrome (FXS). Riluzole is hypothesized to have an inhibitory effect on glutamate release, block excitotoxic effects of glutamate, and potentiate postsynaptic GABA(A) receptor function. Extracellular signal-related kinase (ERK) activation is known to be delayed in humans with FXS and knockout animal models of FXS. Correction of delayed ERK activation is a potential biomarker of treatment response in FXS. We conducted a six-week open-label prospective pilot study of riluzole (100 mg/day) in six adults with FXS. Methods. Riluzole was started at 50 mg every evening and then increased to 50 mg twice daily at week 2. The dose was kept constant for the final 4 weeks of the trial. Clinical response was determined by a score of 1 “very much improved” or 2 “much improved” on the Clinical Global Impressions Improvement (CGI-I) scale and a ≥ 25% improvement on the Children's Yale-Brown Obsessive Compulsive Scale modified for Pervasive Developmental Disorders. The primary target of treatment in this study was repetitive, compulsive behavior that commonly occurs in persons with FXS. The study incorporated an ERK activation biomarker assay. Potential adverse effects were assessed in a systematic manner at all clinic visits and by phone between visits. Results. Riluzole treatment was associated with clinical response in 1 of 6 subjects (17%). Among a number of secondary outcome measures employed, significant improvement was only noted on the ADHD Rating Scale-IV (became non-significant when corrected for multiple comparisons). Riluzole use was associated with significant correction in ERK activation time in all subjects (mean change from 3.82 ± 0.27 (baseline) to 2.99 ± 0.26 (endpoint) minutes; p = 0.007). Riluzole was well tolerated; mean increases in liver function tests occurred but drug discontinuation was not required. Conclusion. Overall, riluzole use was not associated with significant clinical improvement despite uniform correction of peripheral ERK activation. Future directions of study include testing of riluzole in animal models of FXS and assessment of psychotropic monotherapy on ERK activation." @default.
• W2000853219 created "2016-06-24" @default.
• W2000853219 creator A5001035052 @default.
• W2000853219 creator A5007573547 @default.
• W2000853219 creator A5012860439 @default.
• W2000853219 creator A5019555383 @default.
• W2000853219 creator A5034047534 @default.
• W2000853219 creator A5053463157 @default.
• W2000853219 creator A5085647019 @default.
• W2000853219 date "2011-03-01" @default.
• W2000853219 modified "2023-10-15" @default.
• W2000853219 title "Open-label riluzole in fragile X syndrome" @default.
• W2000853219 cites W1588132147 @default.
• W2000853219 cites W1794950817 @default.
• W2000853219 cites W1968533747 @default.
• W2000853219 cites W1969498835 @default.
• W2000853219 cites W1972740284 @default.
• W2000853219 cites W1980309199 @default.
• W2000853219 cites W1982538263 @default.
• W2000853219 cites W1984518477 @default.
• W2000853219 cites W1989757995 @default.
• W2000853219 cites W1995058974 @default.
• W2000853219 cites W1995824400 @default.
• W2000853219 cites W2006526119 @default.
• W2000853219 cites W2007532395 @default.
• W2000853219 cites W2008696909 @default.
• W2000853219 cites W2011321547 @default.
• W2000853219 cites W2017807006 @default.
• W2000853219 cites W2031785254 @default.
• W2000853219 cites W2038561863 @default.
• W2000853219 cites W2040009554 @default.
• W2000853219 cites W2043310964 @default.
• W2000853219 cites W2051143476 @default.
• W2000853219 cites W2057319046 @default.
• W2000853219 cites W2063441624 @default.
• W2000853219 cites W2069544569 @default.
• W2000853219 cites W2075344525 @default.
• W2000853219 cites W2075810411 @default.
• W2000853219 cites W2078544102 @default.
• W2000853219 cites W2080135883 @default.
• W2000853219 cites W2084889756 @default.
• W2000853219 cites W2098860615 @default.
• W2000853219 cites W2115110458 @default.
• W2000853219 cites W2116276594 @default.
• W2000853219 cites W2116795013 @default.
• W2000853219 cites W2117874342 @default.
• W2000853219 cites W2120574495 @default.
• W2000853219 cites W2137992068 @default.
• W2000853219 cites W2139869327 @default.
• W2000853219 cites W2159851687 @default.
• W2000853219 cites W4254230094 @default.
• W2000853219 doi "https://doi.org/10.1016/j.brainres.2010.10.108" @default.
• W2000853219 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21059347" @default.
• W2000853219 hasPublicationYear "2011" @default.
• W2000853219 type Work @default.
• W2000853219 sameAs 2000853219 @default.
• W2000853219 citedByCount "57" @default.
• W2000853219 countsByYear W20008532192012 @default.
• W2000853219 countsByYear W20008532192013 @default.
• W2000853219 countsByYear W20008532192014 @default.
• W2000853219 countsByYear W20008532192015 @default.
• W2000853219 countsByYear W20008532192016 @default.
• W2000853219 countsByYear W20008532192017 @default.
• W2000853219 countsByYear W20008532192018 @default.
• W2000853219 countsByYear W20008532192019 @default.
• W2000853219 countsByYear W20008532192020 @default.
• W2000853219 countsByYear W20008532192021 @default.
• W2000853219 countsByYear W20008532192022 @default.
• W2000853219 countsByYear W20008532192023 @default.
• W2000853219 crossrefType "journal-article" @default.
• W2000853219 hasAuthorship W2000853219A5001035052 @default.
• W2000853219 hasAuthorship W2000853219A5007573547 @default.
• W2000853219 hasAuthorship W2000853219A5012860439 @default.
• W2000853219 hasAuthorship W2000853219A5019555383 @default.
• W2000853219 hasAuthorship W2000853219A5034047534 @default.
• W2000853219 hasAuthorship W2000853219A5053463157 @default.
• W2000853219 hasAuthorship W2000853219A5085647019 @default.
• W2000853219 hasConcept C118552586 @default.
• W2000853219 hasConcept C126322002 @default.
• W2000853219 hasConcept C15744967 @default.
• W2000853219 hasConcept C169760540 @default.
• W2000853219 hasConcept C170493617 @default.
• W2000853219 hasConcept C185592680 @default.
• W2000853219 hasConcept C197934379 @default.
• W2000853219 hasConcept C2777630245 @default.
• W2000853219 hasConcept C2779319286 @default.
• W2000853219 hasConcept C2780648746 @default.
• W2000853219 hasConcept C2781197716 @default.
• W2000853219 hasConcept C55493867 @default.
• W2000853219 hasConcept C61174792 @default.
• W2000853219 hasConcept C71924100 @default.
• W2000853219 hasConcept C98274493 @default.
• W2000853219 hasConceptScore W2000853219C118552586 @default.
• W2000853219 hasConceptScore W2000853219C126322002 @default.
• W2000853219 hasConceptScore W2000853219C15744967 @default.
• W2000853219 hasConceptScore W2000853219C169760540 @default.
• W2000853219 hasConceptScore W2000853219C170493617 @default.
• W2000853219 hasConceptScore W2000853219C185592680 @default.

• next